. 2020 Sep 29;101:283–289. doi: 10.1016/j.ijid.2020.09.1460

Table A1.

Clinical outcome hazard ratio estimates for HCQ and CQ use among COVID19 patients under separate propensity risk models.

N = 1012*		Endpoint: death						Endpoint: ICU admission						Combined endpoint
		Unadjusted			Adjusted³			Unadjusted			Adjusted³			Unadjusted			Adjusted⁴
Model	Drug use	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Overall¹	None (ref)	1.0			1.0			1.0			1.0			1.0			1.0
	CQ	0.64	0.47–0.88	0.007	1.01	0.71–1.44	0.937	1.50	1.05–2.13	0.024	0.91	0.63–1.31	0.619	0.94	0.74–1.18	0.590	0.96	0.75–1.24	0.772
	HCQ	0.62	0.41–0.93	0.020	0.92	0.58–1.46	0.736	0.82	0.49–1.37	0.453	0.56	0.33–0.95	0.031	0.69	0.50–0.95	0.023	0.71	0.51–1.01	0.054
Matched paired²	None (ref)	1.0			1.0			1.0			1.0			1.0			1.0
	CQ	0.66	0.38–1.13	0.130	0.59	0.23–1.52	0.272	0.85	0.53–1.38	0.523	0.82	0.41–1.64	0.567	0.77	0.53–1.10	0.144	0.85	0.50–1.43	0.535
	HCQ	0.66	0.34–1.26	0.207	0.35	0.12–1.03	0.057	0.41	0.22–0.78	0.007	0.48	0.21–1.08	0.075	0.51	0.32–0.81	0.004	0.50	0.28–0.91	0.023
Stratified quintiles²	None (ref)	1.0			1.0			1.0			1.0			1.0			1.0
	CQ	0.77	0.54–1.08	0.124	0.98	0.68–1.41	0.919	0.97	0.67–1.40	0.863	0.79	0.54–1.14	0.204	0.86	0.67–1.11	0.242	0.89	0.69–1.15	0.373
	HCQ	0.84	0.55–1.30	0.431	0.86	0.54–1.39	0.547	0.48	0.29–0.82	0.007	0.50	0.29–0.84	0.010	0.65	0.46–0.91	0.011	0.66	0.46–0.94	0.020
Weighted²	None (ref)	1.0			1.0			1.0			1.0			1.0			1.0
	CQ	0.81	0.58–1.15	0.243	0.94	0.65–1.35	0.732	0.91	0.63–1.32	0.615	0.79	0.55–1.15	0.217	0.85	0.67–1.10	0.205	0.85	0.66–1.10	0.228
	HCQ	0.78	0.52–1.18	0.244	0.93	0.61–1.41	0.734	0.50	0.29–0.85	0.011	0.47	0.27–0.82	0.008	0.66	0.48–0.91	0.011	0.68	0.49–0.95	0.022

¹Cox regression model without propensity score (PS) adjustment; ²PS adjustment – see statistical method section for explanation of the different models; HR = hazard ratio, CI = confidence interval; CQ = chloroquine, HCQ = hydroxychloroquine; ³adjusted for gender, age, comorbidity CVA, comorbidity diabetes, comorbidity asthma/COPD, use of of broad-spectrum antibiotics, therapeutic anticoagulation, prophylactic anticoagulation, first day in ED; ⁴adjusted for gender, age, comorbidity asthma/COPD, use of broad-spectrum antibiotics, prophylactic anticoagulation, first day in ED; *all analyses were stratified by ICU restriction to reflect underlying potential differences in adverse incidences and risk factor prevalences.